Gaining on healthy demand | Value Research Cipla saw a number of management changes in the past couple of years, but it has now entered into the growth phase again
Stock Analyst Choice

Gaining on healthy demand

Cipla saw a number of management changes in the past couple of years, but it has now entered into the growth phase again

09-Sep-2015 •Mohammed Ekramul Haque and Vikas Vardhan

The situation
Cipla suffered a number of changes in the last couple of years. First, Amar Lulla, joint MD, put in his papers in 2011 on health grounds. Then the CMD, Y K Hamied, stepped down in 2013. These were followed by a spate of top-level exits, including the CFO. A change in strategy saw the company buying up its distributors in export markets. Low offtake by the South African government led to sluggish revenue growth in FY15.

What's changed?
After its two-year investment phase ended in FY15, Cipla has now entered into a high growth phase as it ramps up market share in the EU and the US, with improvement in demand in South Africa and resolving of supply-related issues in the domestic market.

Triggers

  • Cipla's inhaler has a market share of 10-15 per cent in Germany and Sweden. It is likely to get UK approval this financial year. It has set a target of 50 per cent share in the UK. The UK constitutes half of the $800 million EU market for the drug.
  • Following low demand in tender sales (government orders) in South Africa last year, recent tender wins and increased government offtake promise better growth this financial year. This business brings in 14 per cent of Cipla's revenues.
  • Cipla sells Nexium at 30 per cent profit sharing with Teva in the US. In the March 2015 quarter, Teva reported $300 million plus sales for Nexium. That should drive Cipla's bottom line.
  • Cipla made 12 filings in FY15. These specialised in respiratory, oncology and anti-infectives. These coupled with Cipla's limited competition products are to drive revenues in the medium term.
  • Supply-related issues impacted domestic sales in FY15. In spite of these issues, Cipla reported an 18 per cent growth (YoY) in domestic sales. Those issues are likely to get resolved in the current year.

What lies ahead?
Cipla's UK push will add to the bottom line as will greater Nexium sales in the US. Improved government buying in South Africa promises further gains.

Valuations
Cipla trades at 45 times earnings. With earnings set to go up, valuations are likely to cool down. Buy.

Other Categories

First Page

Value Research CEO Dhirendra Kumar reflects on pressing issues facing investors today and shares timeless advice to keep them on track.

Investment Options

NPS

Articles about the National Pension System aka NPS, published on Value Research Online.

Value Research Premium

Articles about Value Presearch Premium, showcasing the benefits of taking a premium subscription on Value Research.

Category Compass

In-depth analysis of category trends and performance and updates on fund recommendations

Fund Analysis

Insight

Advice, opinion and guidance not specific to a fund or a category.

Passively Yours

Performance Update

SIP Sahi Hai

Investing via SIPs in mutual funds is a great way to build wealth over time. The articles here tell you exactly why and how.

IPO Analysis

Our analyses of IPOs will answer important questions on the company’s fundamentals, business model, strengths, weaknesses, and of course the valuation of the stock.

Stock Advisor

Value Research Stock Advisor is a premium service that provides subscribers with thoroughly-researched stock recommendations with regular updates. The stories here draw from the Stock Advisor team’s experience researching companies.

Fund News

Check updates from Mutual Funds on dividends, changes to exit loads, NFO announcements, and more.

Fundwire

News, analysis and features on mutual funds.

Newswire

Archive of news updates related to investment regulations, stock markets, mutual funds and more.

Stockwire

News, analysis and features on stocks.

First things...

The very first things a beginner investor needs to know.

Fund Basics

Archive of introductory articles on mutual funds. Especially useful for those are beginners to MF investing.

Fund Update

Views and commentaries on mutual fund trends and developments

How I Did It

Real stories from real investors on their investment journeys – mistakes made, lessons learnt and the ultimate success they finally encountered.

Income Tax Know-how

Stuff you need to know as you file your income tax returns.

Insurance

Before investment comes insurance. Here, we provide guidance on buying adequate cover for you and your family.

Interview

Insightful conversations on the markets, funds, and what matters right now.

Laughing Stock

Learning

Useful articles to help you invest better, whether you are a new investor or well into your investment journey.

Manager Speak

Conversations with investment managers in charge of funds under our Premium Coverage

Mutual Fund Sahi Hai

Mutual funds have revolutionised the way Indians invest, and for good reason too. Read more on what investing in mutual funds involves.

Using Value Research Online

Value Research Online brings to you a wide array of tools and features to invest better, make important decisions and track your portfolio. Learn how you can use them here.

Words Worth

Archive of articles that focus on the investing philosophy of masters like Warren Buffet, Walter Schloss, Charlie Munger and more.